Levomepromazine as adjuvant sedation in a pediatric intensive care unit

Authors

  • Verónica Becerra Terapista intensivo pediátrico, psiquiatra infanto-juvenil. Unidad de Cuidados Intensivos Pediátricos, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
  • Daniel Buamscha Unidad de Cuidados Intensivos Pediátricos, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
  • Corina Ponce Servicio de Salud Mental, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
  • Carlos Cambaceres Unidad de Cuidados Intensivos Pediátricos, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
  • Alejandro Noman Unidad de Cuidados Intensivos Pediátricos, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
  • María Eugenia Galván Unidad de Cuidados Intensivos Pediátricos, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina
  • Miriam Lenz Unidad de Cuidados Intensivos Pediátricos, Hospital de Pediatría Juan P. Garrahan, Buenos Aires, Argentina

Keywords:

Levomepromazine, Sedation, Pediatric ICU

Abstract

Introduction: Sedation of patients in pediatric ICU extubated and in weaning of mechanic ventilation is difficult under regular sedation, because of the tolerance and/or abstinence generated by its sustained use. The objective of this study is to describe the use of Levomepromazine as sedative coadjuvant in these patients. Population and methods: Observational and longitudinal study in intensive care from Juan P. Garrahan Pediatric Hospital. Patients older than 2 years were included, extubated and in weaning of mechanic ventilation with requirements of additional sedation. The level of basal sedation and post-intervention (levomepromazine 0.5 mg/kg every 8 hours) were evaluated with Ramsay and Khalil scales. Doses of regular sedatives were compared before and after the indication. It was considered positive an increase of 1 in the scales, or a decrease of 20% in the regular sedatives doses. Results: 36 patients, medium age of 8,5 years, average doses of levomepromazine 0.38 mg/kg. 97% showed positive result. The regular sedative doses were reduced more than 20% after the intervention. No adverse effects or deceased were registered. 

Downloads

Download data is not yet available.

Published

2023-05-07

How to Cite

Becerra, V., Buamscha, D., Ponce, C., Cambaceres, C., Noman, A., Galván, M. E., & Lenz , M. (2023). Levomepromazine as adjuvant sedation in a pediatric intensive care unit. Vertex Revista Argentina De Psiquiatría, 28(136, nov.-dic.), 411–415. Retrieved from https://revistavertex.com.ar/ojs/index.php/vertex/article/view/399